… of the mechanism by which PARP inhibitors mediate their anti-cancer capacity but may
also increase the subset of patients treated with PARP inhibitors. Since their approval in 2014, …

… to the clinical use of PARP inhibitors, the expected clinical outcomes and potential risks. It
appears that on the cytoprotective aspect of PARP, … years, much, clinically relevant data will be …

… validated the synthetic lethal interaction between inhibition of PARP1, a key … of PARP inhibitor
clinical development, a work that has resulted in the registration of several PARP inhibitors …

… of poly(ADP-ribose) polymerase (PARP) for the … clinical data with PARP inhibitors in various
forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant…

… In most cases, PARP inhibition did not significantly worsen normal tissue toxicity, although
it is often difficult to detect clinically relevant effects on normal tissues in these animal models. …

… -hormone drugs, USP7 inhibitors, BET inhibitors, and immunotherapy. This article reviews
the mechanism of PARP inhibition in the treatment of PC, the progress of clinical research, the …

… This review aimed to focus on the clinic relevance of these drugs, particularly on their
clinical indications and main adverse reactions. Given that they are medicines dispensed …

… Here we review both completed and ongoing clinical trials involving PARP inhibitors and …
with PARP inhibition remains investigational. As monotherapy, several PARP inhibitors have …

… Therefore, determining how to use PARP inhibitors in more clinical … for the application of
PARP inhibitors in pancreatic cancer. … The successful results of clinical trials for PARP inhibitors …

… In this review, we reviewed the underlying mechanisms of PARP inhibitor resistance in
detail and summarized the potential strategies to overcome PARPi resistance and increase …